Review article · 2026 · Open access
Expert viewpoint on endpoints in systemic sclerosis: current and future outlook
RMD Open, 12(3), e006784 · Published 1 July 2026 · DOI 10.1136/rmdopen-2026-006784
In brief
“Expert viewpoint on endpoints in systemic sclerosis: current and future outlook” is a 2026 review article by Anna‐Maria Hoffmann‐Vold and 10 co-authors, published in RMD Open. OpenAlex counts 1 citations as of 22 November 2026. It is open access under a CC BY licence: the full text is free to read at RMD Open.
- Citations
- 1
- Most cited in
- 2026 (1)
- Field-weighted impact
- 0.82
- References
- 57
- Authors
- 11
Abstract
Systemic sclerosis (SSc) is a rare, heterogeneous, systemic autoimmune rheumatic disease characterised by vasculopathy, immune dysregulation and fibrosis affecting multiple organ systems. The complexity and variability of SSc manifestations pose significant challenges for clinical trial design and endpoint selection. Historically, three types of trial concepts have emerged: studies focused on a single organ; studies suggesting disease modification by combining a primary single-organ endpoint with supportive secondary endpoints across other systems, and studies explicitly designed to demonstrate disease modification through combined endpoints.This expert review explores the current landscape and future directions of clinical endpoints in SSc trials. It highlights the growing importance of patient-reported outcomes, such as the Health Assessment Questionnaire-Disability Index and ScleroID, which provide valuable insights into patient experiences. The review also discusses the emergence of candidate composite endpoints, including the revised Composite Response Index in Systemic Sclerosis, which integrates clinical, functional and patient-centred measures to better reflect treatment efficacy.Despite progress, significant unmet needs remain. Many endpoints assess damage at advanced stages, underscoring the need for earlier indicators of disease progression. The review advocates for incorporating time-to-event analyses, imaging and biomarker-based assessments to enhance sensitivity and relevance. It also emphasises the importance of refining composite endpoints to include continuous measures and broader domains such as vascular and gastrointestinal involvement. These efforts aim to improve the design and interpretability of SSc clinical trials, ultimately enhancing therapeutic development and patient outcomes.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Hoffmann‐Vold, A., Distler, O., Del Galdo, F., Distler, J. H. W., Allanore, Y., Bernstein, E. J., Denton, C. P., Kuwana, M., Matucci‐Cerinic, M., Alves, M., & Smith, V. M. (2026). Expert viewpoint on endpoints in systemic sclerosis: current and future outlook. RMD Open, 12(3), e006784. https://doi.org/10.1136/rmdopen-2026-006784
MLA 9
Hoffmann‐Vold, Anna‐Maria, et al. “Expert viewpoint on endpoints in systemic sclerosis: current and future outlook.” RMD Open, vol. 12, no. 3, 2026, p. e006784. https://doi.org/10.1136/rmdopen-2026-006784.
Chicago
Hoffmann‐Vold, Anna‐Maria, Oliver Distler, Francesco Del Galdo, Jörg H. W. Distler, Yannick Allanore, Elana J. Bernstein, Christopher Paul Denton, et al. 2026. “Expert viewpoint on endpoints in systemic sclerosis: current and future outlook.” RMD Open 12 (3): e006784. https://doi.org/10.1136/rmdopen-2026-006784.
Harvard
Hoffmann‐Vold, A. et al. (2026) ‘Expert viewpoint on endpoints in systemic sclerosis: current and future outlook’, RMD Open, 12(3), p. e006784. doi:10.1136/rmdopen-2026-006784.
IEEE
A. Hoffmann‐Vold et al., “Expert viewpoint on endpoints in systemic sclerosis: current and future outlook,” RMD Open, vol. 12, no. 3, p. e006784, 2026, doi: 10.1136/rmdopen-2026-006784.
BibTeX
@article{hoffmannvold2026expert,
title = {{Expert viewpoint on endpoints in systemic sclerosis: current and future outlook}},
author = {Hoffmann‐Vold, Anna‐Maria and Distler, Oliver and Del Galdo, Francesco and Distler, Jörg H. W. and Allanore, Yannick and Bernstein, Elana J. and Denton, Christopher Paul and Kuwana, Masataka and Matucci‐Cerinic, Marco and Alves, Margarida and Smith, Vanessa M.},
journal = {RMD Open},
year = {2026},
volume = {12},
number = {3},
pages = {e006784},
doi = {10.1136/rmdopen-2026-006784},
url = {https://doi.org/10.1136/rmdopen-2026-006784}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- systemic sclerosis
- clinical trial endpoints
- composite endpoints
- patient-reported outcomes
- HAQ-DI
- disease modification
- survival analysis
- imaging biomarkers
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Hoffmann‐Vold, A., Distler, O., Del Galdo, F., Distler, J. H. W., Allanore, Y., Bernstein, E. J., Denton, C. P., Kuwana, M., Matucci‐Cerinic, M., Alves, M., & Smith, V. M. (2026). Expert viewpoint on endpoints in systemic sclerosis: current and future outlook. RMD Open, 12(3), e006784. https://doi.org/10.1136/rmdopen-2026-006784
How many times has this paper been cited?
1 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at RMD Open: sign in and open the PDF from this page.
Who wrote this paper?
Anna‐Maria Hoffmann‐Vold, Oliver Distler, Francesco Del Galdo, Jörg H. W. Distler, Yannick Allanore, Elana J. Bernstein, Christopher Paul Denton, Masataka Kuwana, Marco Matucci‐Cerinic, Margarida Alves, Vanessa M. Smith.
What is the DOI of this paper?
10.1136/rmdopen-2026-006784, permanently at https://doi.org/10.1136/rmdopen-2026-006784. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.